Onyema Ogbuagu, MBBCh, FACP, FIDSA
This activity is jointly provided by Global Education Group and Integritas Communications.
This educational activity is supported by an educational grant from AstraZeneca.
Onyema Ogbuagu, MBBCh, FACP, FIDSA
Associate Professor of Medicine
Director, HIV Clinical Trials Program
Section of Infectious Diseases
Yale School of Medicine
New Haven, Connecticut
This activity is intended for infectious disease, internal medicine, and other clinicians involved in the management of patients with mild or moderate coronavirus disease (COVID-19) who are at risk for clinical progression.
Because COVID-19 is such a rapidly evolving disease, clinicians struggle to stay current on EUA status for anti-SARS-CoV-2 monoclonal antibodies (mAbs), particularly in light of the Omicron variant that emerged late 2021. This has brought changes to EUAs, new data, and both supply and staffing shortages for treatment and prevention of COVID-19. Clinicians also lack familiarity with recent EUAs for preexposure prophylaxis, identifying eligible immunocompromised patients, and NIH guidelines for this new therapy. Dr. Onyema Ogbuagu discusses developments in COVID-19 related to the Omicron variant, new EUAs for preexposure prophylaxis, updates to treatment guidelines, and strategies to address healthcare disparities.
After completing this activity, the participant should be better able to:
- Review recent clinical trial data for anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies as treatments or prophylactic therapies
- Treat patients who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current guidelines from the US Food and Drug Administration
- Describe the effects of recent variants on the use of anti-SARS-CoV-2 monoclonal antibodies
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 0.5 contact hour(s) (which includes 0.0 hour(s) of pharmacology).
Instructions to Receive Credit
In order to receive credit for this activity, the participant must score 70% or better on the posttest and complete the program evaluation.
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Term of Offering
This activity was released on February 23, 2022 and is valid for one year. Requests for credit must be made no later than February 23, 2023.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Onyema Ogbuagu, MBBCh, FACP, FIDSA: Consulting Fees: Gilead Sciences, Inc., ViiV Healthcare
The planners and managers have the following relevant financial relationships with ineligible companies:
Kristin Delisi, NP: Nothing to disclose.
Lindsay Borvansky: Nothing to disclose.
Andrea Funk: Nothing to disclose.
Liddy Knight: Nothing to disclose.
Ashley Cann: Nothing to disclose.
Gena Dolson: Nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.Begin Activity
credit amount 0.50
credit type CME/AANP
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment